S A Cannistra

1.3k total citations
24 papers, 1.1k citations indexed

About

S A Cannistra is a scholar working on Oncology, Reproductive Medicine and Immunology. According to data from OpenAlex, S A Cannistra has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Reproductive Medicine and 7 papers in Immunology. Recurrent topics in S A Cannistra's work include Ovarian cancer diagnosis and treatment (10 papers), Immune Response and Inflammation (5 papers) and Immune Cell Function and Interaction (4 papers). S A Cannistra is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Immune Response and Inflammation (5 papers) and Immune Cell Function and Interaction (4 papers). S A Cannistra collaborates with scholars based in United States, Germany and India. S A Cannistra's co-authors include Thomas Ströbel, H Levine, James D. Griffin, F. Herrmann, Linda J. Swanson, Jonathan M. Niloff, Yu‐Tzu Tai, J D Griffin, Graziella M. Abu‐Jawdeh and P Groshek and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

S A Cannistra

24 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S A Cannistra United States 15 405 368 324 236 141 24 1.1k
Martha Hayden-Ledbetter United States 13 381 0.9× 763 2.1× 299 0.9× 405 1.7× 36 0.3× 18 1.5k
K L Simpson United Kingdom 15 361 0.9× 498 1.4× 134 0.4× 76 0.3× 186 1.3× 16 1.1k
Fumitaka Numa Japan 17 361 0.9× 101 0.3× 165 0.5× 156 0.7× 25 0.2× 42 800
Leonardo Mirandola United States 20 606 1.5× 512 1.4× 439 1.4× 43 0.2× 188 1.3× 58 1.1k
Brian P. Mullaney United States 18 352 0.9× 60 0.2× 467 1.4× 263 1.1× 34 0.2× 25 1.1k
Yao-Qi Huang United States 15 445 1.1× 158 0.4× 241 0.7× 76 0.3× 543 3.9× 17 1.2k
R. L. Ceriani United States 12 566 1.4× 355 1.0× 222 0.7× 45 0.2× 28 0.2× 26 992
G. E. Moore United States 18 336 0.8× 223 0.6× 258 0.8× 40 0.2× 66 0.5× 51 882
Mitsuo Yoshinouchi Japan 22 906 2.2× 189 0.5× 512 1.6× 213 0.9× 18 0.1× 57 1.6k
Yoichi Shibata Japan 25 413 1.0× 743 2.0× 335 1.0× 73 0.3× 759 5.4× 76 1.9k

Countries citing papers authored by S A Cannistra

Since Specialization
Citations

This map shows the geographic impact of S A Cannistra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S A Cannistra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S A Cannistra more than expected).

Fields of papers citing papers by S A Cannistra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S A Cannistra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S A Cannistra. The network helps show where S A Cannistra may publish in the future.

Co-authorship network of co-authors of S A Cannistra

This figure shows the co-authorship network connecting the top 25 collaborators of S A Cannistra. A scholar is included among the top collaborators of S A Cannistra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S A Cannistra. S A Cannistra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiong, Niya, Nabihah Tayob, Carolyn Krasner, et al.. (2020). LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Annals of Oncology. 31. S1165–S1165. 11 indexed citations
2.
Herold, Christina I., Wenjie Luo, Richard T. Penson, et al.. (2018). A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer. Annals of Oncology. 29. viii334–viii335. 20 indexed citations
3.
Konstantinopoulos, Panagiotis A., Carolyn Krasner, Mary K. Buss, et al.. (2018). Phase II, two-stage study of avelumab in patients with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer. Gynecologic Oncology. 149. 24–25. 5 indexed citations
4.
5.
Campos, Susana M., Don S. Dizon, S A Cannistra, et al.. (2007). Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers. Journal of Clinical Oncology. 25(18_suppl). 5517–5517. 10 indexed citations
6.
Cannistra, S A, U. Matulonis, Richard T. Penson, et al.. (2006). Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clinical Oncology. 24(18_suppl). 5006–5006. 43 indexed citations
7.
Cannistra, S A, Michael V. Seiden, Carolyn Krasner, et al.. (2006). Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. Journal of Clinical Oncology. 24(18_suppl). 5020–5020. 14 indexed citations
8.
Tai, Yu‐Tzu, Thomas Ströbel, Donald Küfe, & S A Cannistra. (1999). In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.. PubMed. 59(9). 2121–6. 74 indexed citations
9.
Tai, Yu‐Tzu, et al.. (1998). BAX protein expression and clinical outcome in epithelial ovarian cancer.. Journal of Clinical Oncology. 16(8). 2583–2590. 118 indexed citations
10.
Ströbel, Thomas, Linda J. Swanson, & S A Cannistra. (1997). In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.. PubMed. 57(7). 1228–32. 111 indexed citations
11.
Abu‐Jawdeh, Graziella M., Timothy W. Jacobs, Jonathan M. Niloff, & S A Cannistra. (1996). Estrogen Receptor Expression Is a Common Feature of Ovarian Borderline Tumors. Gynecologic Oncology. 60(2). 301–307. 56 indexed citations
12.
Ottensmeier, Christian H., Linda J. Swanson, Thomas Ströbel, et al.. (1996). Absence of constitutive EGF receptor activation in ovarian cancer cell lines. British Journal of Cancer. 74(3). 446–452. 13 indexed citations
13.
Cannistra, S A, Graziella M. Abu‐Jawdeh, Jonathan M. Niloff, et al.. (1995). CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.. Journal of Clinical Oncology. 13(8). 1912–1921. 81 indexed citations
14.
Cannistra, S A, et al.. (1995). Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.. PubMed. 1(3). 333–42. 38 indexed citations
15.
Tepler, I, S A Cannistra, Emil Frei, et al.. (1993). Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.. Journal of Clinical Oncology. 11(8). 1583–1591. 67 indexed citations
16.
Cannistra, S A. (1991). Growth regulation of malignant clonogenic cells in acute myeloid leukemia. Current Opinion in Oncology. 3(1). 4–12. 7 indexed citations
17.
Herrmann, F., S A Cannistra, A Lindemann, et al.. (1989). Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2.. The Journal of Immunology. 142(1). 139–143. 59 indexed citations
18.
Herrmann, F., A. Lindemann, S A Cannistra, et al.. (1989). Monocyte Interleukin-1 Secretion Is Regulated by the Sequential Action of γ-Interferon and Interleukin-2 Involving Monocyte Surface Expression of Interleukin-2 Receptors. Hämatologie und Bluttransfusion. 32. 299–315. 1 indexed citations
19.
Cannistra, S A, P Groshek, & J D Griffin. (1988). Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor.. PubMed. 16(10). 865–70. 18 indexed citations
20.
Herrmann, F., S A Cannistra, H Levine, & James D. Griffin. (1985). Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells.. The Journal of Experimental Medicine. 162(3). 1111–1116. 233 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martha Hayden-Ledbetter Breakdown of academic impact, for papers by K L Simpson Breakdown of academic impact, for papers by Fumitaka Numa Breakdown of academic impact, for papers by Leonardo Mirandola Breakdown of academic impact, for papers by Brian P. Mullaney Breakdown of academic impact, for papers by Yao-Qi Huang Breakdown of academic impact, for papers by R. L. Ceriani Breakdown of academic impact, for papers by G. E. Moore Breakdown of academic impact, for papers by Mitsuo Yoshinouchi Breakdown of academic impact, for papers by Yoichi Shibata
Rankless by CCL
2026